InvestSMART

Noxopharm Limited (ASX: NOX) - Share Price

- Current share price for NOX : $0.050

Noxopharm Limited (NOX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a range of mRNA medicines. The company utilises in house capabilities and strategic partnerships with researchers to build a growing pipeline of new proprietary drugs based on two technology platforms - Sofra (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma (oncology).

NOX General Information +

ASX Code NOX
Website http://www.noxopharm.com
Industry/Sector Biotechnology
Market Cap ($M) 15
NOX Share Price $0.050
Day High $0.050
Day Low $0.050
Last Close $0.050
NOX Share Price Movement - ( No change )
Prices as at 16:40, 20 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Noxopharm Limited (NOX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Noxopharm Limited (NOX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Noxopharm Limited (NOX) price-sensitive announcements

NOX - Novel oligonucleotides data presented at Options Conference
Noxopharm Limited announced that data presented at the ISRV Options for the Control of Inf
Noxopharm Limited (NOX)
1 Sep 2026 | 9:36 AM
NOX - Appendix 4E - Preliminary Financial Report
Noxopharm Limited’s Appendix 4E Preliminary Financial Report for the Australian financial
Noxopharm Limited (NOX)
28 Aug 2026 | 4:34 PM
NOX - New preclinical data supports immuno-oncology approach
Noxopharm Limited has announced promising new preclinical data from their Sofra™ technolog
Noxopharm Limited (NOX)
26 Aug 2026 | 8:06 AM
NOX - Quarterly Activities/Appendix 4C Cash Flow Report
Noxopharm Limited, an Australian clinical-stage biotech company, reported on its quarterly
Noxopharm Limited (NOX)
22 Jul 2026 | 8:26 AM

Noxopharm Limited (NOX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Noxopharm Limited (NOX)
ORDINARY FULLY PAID
 Health Care $15 2026 AGM Letter of Access, Notice of Meeting and Proxy 16 Oct 2026 11:50AM $0.050 $0.050 fallen by 0%
Noxopharm Limited (NOX)
ORDINARY FULLY PAID
 Health Care $15 Appendix 4G and Corporate Governance Statement 16 Oct 2026 10:45AM $0.050 $0.050 fallen by 0%
Noxopharm Limited (NOX)
ORDINARY FULLY PAID
 Health Care $15 Annual Report to shareholders 16 Oct 2026 10:32AM $0.050 $0.050 fallen by 0%
Noxopharm Limited (NOX)
ORDINARY FULLY PAID
 Health Care $15 FDA feedback supports SOF-SKN Phase II plans 8 Oct 2026 8:15AM $0.062 $0.050 fallen by 19.35%
Noxopharm Limited (NOX)
ORDINARY FULLY PAID
 Health Care $15 Audited Financial Statements 30 Sep 2026 4:05PM $0.059 $0.050 fallen by 15.25%
Noxopharm Limited (NOX)
ORDINARY FULLY PAID
 Health Care $15 SOF-SKN to progress to extension study in CLE patients 14 Sep 2026 8:23AM $0.072 $0.050 fallen by 30.56%

NOX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$4.46 -$1.50 -10.20% 0.00 0.00 0.00% 0.0%
2025A -$4.88 -$1.70 36.90% 0.00 0.00 0.00% 0.0%
2024A -$3.58 -$1.20 -76.30% 0.00 0.00 0.00% 0.0%

NOX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $92,234M 0.7309 -0.4410 0.0602 11.9072 21.3018 20.0926 2.21% 2.21% 2.28%
Mesoblast Limited (MSB) $2,590M -0.4501 0.0000 0.0000 0.0000 0.0000 310.9375 0.00% 0.00% 0.00%
Noxopharm Limited (NOX) $15M -0.1018 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,880M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,353M -1.3893 0.0000 -0.5230 0.0000 185.7143 389.3564 0.00% 0.00% 0.00%

NOX Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 -4.20 0.00
Market 0.31 13.50 1.04 0.71
Sector 0.78 42.00 2.55 2.04

NOX Directors

Name Position Start Date
Dr Gisela Mautner Chief Executive Officer, Managing Director 1 Feb 2022
Mr Boris Patkin Non-Executive Director 25 Mar 2020
Mr Frederick (Fred) Bart Non-Executive Director, Non-Executive Chairman 8 May 2020
Mr Peter Ashley Marks Non-Executive Director, Non-Executive Deputy Chairman 15 Mar 2016

Noxopharm Limited (NOX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
25 May 2026 PATKIN, Boris Transfer Direct Shares 630,000 $0.060 $37,800.000
25 May 2026 PATKIN, Boris Transfer Indirect Shares 630,000 $0.060 $37,800.000
12 Dec 2025 BART, Frederick (Fred) Issued Convertibles 1,250,000 $1.000 $1,250,000.000

See all changes in directors' interest & trades for Noxopharm Limited (NOX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NOX Management

Name Position
Shawn Pieter Van Boheemen Company Secretary

NOX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Noxopharm Limited (NOX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
34,249,106 (11.72%) Milligene Pty Ltd

NOX Calendar of Events

Date Event
15 October 2027 Report (Annual)
29 September 2027 Report (Annual)
27 August 2027 Report (Prelim)
26 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.